N
NuPulse
NuPulse a medical device developing novel technology to treat patients with heart failure, one of the leading causes of death worldwide
About NuPulse
NuPulseCV, Inc., based in Raleigh, NC, is pioneering advancements in the treatment of advanced heart failure through its investigational device, the intravascular ventricular assist system (iVAS). The iVAS is a minimally invasive device designed to support heart function and improve patient outcomes. It is currently being evaluated in clinical trials in the United States and is not yet available for sale. The device aims to allow patients to be discharged from the hospital, thereby improving their quality of life and reducing healthcare costs. NuPulseCV primarily serves patients with advanced heart failure and collaborates with qualified investigators and healthcare providers to ensure the efficacy and safety of its device. The company operates in the medical device market, focusing on innovative solutions for cardiac care. Its business model revolves around the development, clinical evaluation, and eventual commercialization of the iVAS device. Revenue generation is anticipated through the sale of the device upon regulatory approval and widespread adoption in clinical settings.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Raleigh, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Venture Connect
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NuPulse on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NuPulse on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.